Skip to main content

This translation is provided for general access and has no recorded medical-language review.

Editorial general information — not a clinical-review record

Published: Updated: Publisher: Dr. Murat Toktamışoğlu

How is the boundary between a cosmetic, medical device and biological exosome product verified?

Calling a product a cosmetic, serum, medical device or research product does not determine its classification. Composition, intended use, disease or tissue claims, route and local law matter together; a foreign registration number does not authorize injection in Türkiye.

This translation has no recorded clinical or medical-language review.

Direct answer

  • The package classification should match an official database and the current intended use.
  • Injecting a product offered for topical use creates different risk and regulatory questions.
  • Research on an ingredient does not establish authorization of a commercial product.

What determines classification?

Regulatory assessment considers more than a name: manufacturer claims, composition, mechanism, intended user, route and promotion all matter. A moisturizing claim differs from wound healing or disease treatment. A claimed cell-derived biological content can introduce additional manufacturing and safety questions. Confirm the Turkish category through TİTCK and the relevant official record rather than relying on a distributor's description.

Match the document to the product

Compare manufacturer, exact trade name, model or catalogue code, lot, scope, date, issuing body and intended use on a certificate with the package. CE marking, FDA establishment registration, an NDC-like number, a trial record and an export certificate are not interchangeable. A document for another family, topical use or only a factory is not evidence of injection or Turkish marketing authorization.

The route-of-use boundary

A topical cosmetic is not automatically suitable after barrier-disrupting microneedling or for injection. Sterility, endotoxin, particles, immune response and systemic exposure change with route. Treatment may be deferred when labeling does not support the proposed route. The US FDA warning does not define Turkish law, but it demonstrates why an 'FDA approved' claim needs exact documentary verification.

Scope of this article

This content is not diagnosis, prescribing, personal risk assessment or a treatment plan. Sources may be limited to a particular product, device, task, indication or study group.

Sources and evidence limits

These links are editorial starting points used to examine the article's boundaries.

  1. Microneedling for Facial Rejuvenation: A Systematic Review

    Foppiani JA et al. · 2025

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  2. Evaluating the Effectiveness and Safety of Radiofrequency for Face and Neck Rejuvenation: A Systematic Review

    Austin GK, Struble SL, Quatela VC · 2022

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  3. Energy-Based Devices for the Treatment of Facial Skin Conditions in Skin of Color

    Sanyal RD, Fabi SG · 2024

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  4. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication

    U.S. Food and Drug Administration (FDA) · 2025

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  5. A Systematic Review and Meta-Analysis of Efficacy, Safety, and Satisfaction Rates of Laser Combination Treatments vs Laser Monotherapy in Skin Rejuvenation Resurfacing

    Pour Mohammad A et al. · 2023

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  6. Outcomes and Adverse Effects of Ablative vs Nonablative Lasers for Skin Resurfacing: A Systematic Review of 1093 Patients

    Mirza HN, Mirza FN, Khatri KA · 2021

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  7. Medical Lasers

    U.S. Food and Drug Administration (FDA) · 2023

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  8. Public Safety Alert Due to Marketing of Unapproved Stem Cell and Exosome Products

    U.S. Food and Drug Administration (FDA) · 2019

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  9. Minimal Information for Studies of Extracellular Vesicles (MISEV2023): From Basic to Advanced Approaches

    International Society for Extracellular Vesicles consensus authors · 2024

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  10. A Systematic Review and Meta-analysis of Clinical Trials Assessing Safety and Efficacy of Human Extracellular Vesicle-Based Therapy

    Systematic review authors · 2024

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review